BIN2

Across TCGA pan-cancer cohorts, BIN2 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated BIN2 data layer compared with 25 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in sarcoma (SARC), where higher BIN2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated BIN2 expression acts as an unfavorable survival marker, although some lineages such as COAD show a favorable association.

SARC, SKCM, and COAD are the cancer types where BIN2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SARC	DFS	Median	All	0.121	0.611	.041	6	view →
SKCM	DFS	Median	III,IV	0.087	0.647	.013	3	view →
COAD	DFS	Median	II,III,IV	1.000	0.425	.044	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

BIN2–SARC (DFS)

Open the SARC breakdown →